Product Information
Registration Status: ActiveHORF LOZENGES is approved to be sold in Singapore with effective from 1996-05-02. It is marketed by YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD, with the registration number of SIN08535P.
This product contains Benzocaine 2mg, and Chlorhexidine 5mg in the form of LOZENGE. It is approved for ORAL use.
This product is manufactured by Y S P INDUSTRIES (M) SDN BHD in MALAYSIA.
It is a Pharmacy Only Medicine that can be obtained from a pharmacist at a retail pharmacy.
Description
A surface anesthetic that acts by preventing transmission of impulses along nerve fibers and at nerve endings. [PubChem]
Indication
For general use as a lubricant and topical anesthetic on esophagus, larynx, mouth, nasal cavity, rectum, respiratory tract or trachea, urinary tract, vagina. It is also used to suppress gag reflex.
Mechanism of Action
Benzocaine binds to sodium channels and reversibly stabilizes the neuronal membrane which decreases its permeability to sodium ions. Depolarization of the neuronal membrane is inhibited thereby blocking the initiation and conduction of nerve impulses.
Toxicity
LD50=3040 mg/kg (rat, oral)
Active Ingredient/Synonyms
4-aminobenzoic acid ethyl ester | Amben ethyl ester | Benzocaina | Benzocaine | Benzocainum | Ethyl Aminobenzoate | Ethyl p-Aminobenzoate | Ethyl p-Aminophenylcarboxylate | p-(Ethoxycarbonyl)aniline | p-Carbethoxyaniline | p-Ethoxycarboxylic Aniline | Benzocaine |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.
Description
A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque. [PubChem]
Indication
For reduction of pocket depth in patients with adult periodontitis, used as an adjunct to scaling and root planing procedures. Also for prevention of dental caries, oropharyngeal decontamination in critically ill patients, hand hygiene in health-care personnel, general skin cleanser, and catheter site preparation and care.
Mechanism of Action
Chlorhexidine's antimicrobial effects are associated with the attractions between chlorhexidine (cation) and negatively charged bacterial cells. After chlorhexidine is absorpted onto the organism's cell wall, it disrupts the integrity of the cell membrane and causes the leakage of intracellular components of the organisms.
Pharmacokinetics
- Absorption
- Absorption of chlorhexidine from the gastrointestinal tract is very poor. Additionally, an in vivo study in 18 adult patients found no detectable plasma or urine chlorhexidine concentrations following insertion of four periodontal implants under clinical conditions.
- Distribution
- Metabolism
- Elimination
Toxicity
LD50= 2g/kg (human, oral); LD50= 3 g/kg (rat, oral); LD50= 2.5 g/kg (mice, oral); LD50= 21 mg/kg (male rat, IV); LD50= 23 mg/kg (female rat, IV); LD50= 25 mg/kg (male mice, IV); LD50= 24 mg/kg (female mice, IV); LD50= 1g/kg (rat, subcutaneous); LD50= 637 mg/kg (male mice, subcutaneous); LD50= 632 mg/kg (female mice, subcutaneous)
Active Ingredient/Synonyms
1,1'-Hexamethylene bis(5-(P-chlorophenyl)biguanide) | Chlorhexidin | Chlorhexidine | Chlorhexidinum | Cloresidina | Clorhexidina | N,N'-bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide | Chlorhexidine |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.